Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofersen in Presymptomatic Adults With a Confirmed SOD1 Mutation
NCT04856982Phase 3Active, not recruiting
- Sponsor
- Biogen
- Start
- May 2021
- Primary completion
- Aug 2027
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 14
01
Overview
A Phase 3 trial of tofersen in amyotrophic lateral sclerosis (ALS), sponsored by Biogen. Started May 2021; status: active, not recruiting.
02
Drugs
tofersen
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT04856982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04856982.